DMK

DMK Pharmaceuticals (DMK)

DMK Pharmaceuticals Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:DMK

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/22	03 : 23	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/02/08	07 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/02/07	00 : 04	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/02/05	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/02/01	07 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/01/24	07 : 23	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/01/24	07 : 22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/01/04	07 : 03	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/01/04	07 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2024/01/04	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/12/22	02 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/12/21	22 : 15	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/12/05	06 : 47	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/12/05	06 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/29	06 : 41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/28	22 : 05	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/16	06 : 39	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/16	06 : 20	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/16	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/16	06 : 06	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/15	05 : 57	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/14	21 : 30	GlobeNewswire Inc.	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/14	00 : 52	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/03	05 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/11/03	05 : 31	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/10/30	20 : 30	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/10/26	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/10/26	06 : 01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/10/21	05 : 15	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:DMK	DMK Pharmaceuticals Corporation
2023/10/20	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation